share_log

8-K: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

8-K: Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

8-K：百時美施貴寶公佈2024年第三季度財務業績
美股SEC公告 ·  10/31 22:55

牛牛AI助理已提取核心訊息

On October 31, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the third quarter of 2024. The company reported revenues of $11.9 billion, marking an 8% increase compared to the same period in the previous year, with a notable 10% increase when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio, which includes products like Reblozyl, Breyanzi, Camzyos, and Opdualag. U.S. revenues rose by 9% to $8.2 billion, while international revenues saw a 7% increase to $3.7 billion. GAAP earnings per share (EPS) were reported at $0.60, while non-GAAP EPS stood at $1.80. The company also highlighted the U.S. approval of Cobenfy, a new treatment for schizophrenia, and raised its revenue guidance for 2024 to approximately 5%, with non-GAAP EPS estimates increased to a range of $0.75 to $0.95. The financial report included reconciliations between non-GAAP financial measures and comparable GAAP financial measures, with reasons for presenting such non-GAAP financial measures.
On October 31, 2024, Bristol-Myers Squibb Company (BMS) released its financial results for the third quarter of 2024. The company reported revenues of $11.9 billion, marking an 8% increase compared to the same period in the previous year, with a notable 10% increase when adjusted for foreign exchange impacts. The growth was primarily driven by the company's Growth Portfolio, which includes products like Reblozyl, Breyanzi, Camzyos, and Opdualag. U.S. revenues rose by 9% to $8.2 billion, while international revenues saw a 7% increase to $3.7 billion. GAAP earnings per share (EPS) were reported at $0.60, while non-GAAP EPS stood at $1.80. The company also highlighted the U.S. approval of Cobenfy, a new treatment for schizophrenia, and raised its revenue guidance for 2024 to approximately 5%, with non-GAAP EPS estimates increased to a range of $0.75 to $0.95. The financial report included reconciliations between non-GAAP financial measures and comparable GAAP financial measures, with reasons for presenting such non-GAAP financial measures.
施貴寶公司（BMS）於2024年10月31日發佈了2024年第三季度的財務業績。公司報告顯示營業收入爲$119億，較去年同期增長8%，在考慮匯率期貨影響後，增長了10%。增長主要受公司的增長組合推動，該組合包括Reblozyl、Breyanzi、Camzyos和Opdualag等產品。美國營收增長了9%，達到$82億，而國際營收增長了7%，達到$37億。根據普通會計準則，每股收益（EPS）爲$0.60，而非普通會計準則下的EPS爲$1.80。公司還強調了Cobenfy在美國獲批，這是一種治療精神分裂症的新療法，並將2024年的營收指導提高到約5%，非普通會計準則下的EPS預估範圍提高至$0.75至$0.95。財務報告包括非普通會計準則財務指標和可比普通會計準則財務指標之間的調和，並說明了爲什麼提出這樣的非普通會計準則財務指標。
施貴寶公司（BMS）於2024年10月31日發佈了2024年第三季度的財務業績。公司報告顯示營業收入爲$119億，較去年同期增長8%，在考慮匯率期貨影響後，增長了10%。增長主要受公司的增長組合推動，該組合包括Reblozyl、Breyanzi、Camzyos和Opdualag等產品。美國營收增長了9%，達到$82億，而國際營收增長了7%，達到$37億。根據普通會計準則，每股收益（EPS）爲$0.60，而非普通會計準則下的EPS爲$1.80。公司還強調了Cobenfy在美國獲批，這是一種治療精神分裂症的新療法，並將2024年的營收指導提高到約5%，非普通會計準則下的EPS預估範圍提高至$0.75至$0.95。財務報告包括非普通會計準則財務指標和可比普通會計準則財務指標之間的調和，並說明了爲什麼提出這樣的非普通會計準則財務指標。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間